DNLIDenali Therapeutics Inc.

DNLI Stock Price, Valuation & Chart | Denali Therapeutics Inc.

Compare

$23.270-0.49 (-2.08%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology DNLI intrinsic value DNLI calculated fair value vs price

Overview Financials Dividends Ratios

DNLI Historical price chart

DNLI Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.69B

PE Ratio-8.08

EPS-2.88

Trading Volume1.43M

Today's High/Low23.68/23.07

Dividend Yield0.00

52 Week High/Low27.3/12.58

Shares Outstanding158.71M

DNLI Financial Statement

DNLI Analyst ratings

DNLI Analysis & performance metrics

DNLI Company profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers…

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company…

DNLI Management team

Name

Position

Tyler M. Nielsen

Senior Vice President of Corporate Finance

Alexander O. Schuth M.D.CFO

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

Marc Tessier-Lavigne Ph.D.CTO

Co-Founder & Independent Director

Mark Rowen

Vice President of Corporate Development

Ryan J. Watts Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Joe Lewcock Ph.D.

Chief Scientific Officer

Laura Hansen Ph.D.

Vice President of Investor Relations

Dana Andersen

Chief Technical and Manufacturing Officer

Name

Position

Tyler M. Nielsen

Senior Vice President of Corporate Finance

Alexander O. Schuth M.D.CFO

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

Marc Tessier-Lavigne Ph.D.CTO

Co-Founder & Independent Director

Mark Rowen

Vice President of Corporate Development

Ryan J. Watts Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Joe Lewcock Ph.D.

Chief Scientific Officer

Laura Hansen Ph.D.

Vice President of Investor Relations

Dana Andersen

Chief Technical and Manufacturing Officer

Management Team

Tyler M. Nielsen

Senior Vice President of Corporate Finance

Alexander O. Schuth M.D.CFO

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

Marc Tessier-Lavigne Ph.D.CTO

Co-Founder & Independent Director

Mark Rowen

Vice President of Corporate Development

Ryan J. Watts Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Joe Lewcock Ph.D.

Chief Scientific Officer

Laura Hansen Ph.D.

Vice President of Investor Relations

Dana Andersen

Chief Technical and Manufacturing Officer

Management

Tyler M. Nielsen

Senior Vice President of Corporate Finance

Alexander O. Schuth M.D.CFO

Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary

Marc Tessier-Lavigne Ph.D.CTO

Co-Founder & Independent Director

Mark Rowen

Vice President of Corporate Development

Ryan J. Watts Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Joe Lewcock Ph.D.

Chief Scientific Officer

Laura Hansen Ph.D.

Vice President of Investor Relations

Dana Andersen

Chief Technical and Manufacturing Officer

Total 8 executives

DNLI Frequently asked questions

What is Denali Therapeutics Inc. (DNLI) Stock Price?

Current stock price of Denali Therapeutics Inc. (DNLI) stock is $23.270. The stock price is -2.08% lower in the session. The intraday range can be seen from this page. Volume of Denali Therapeutics Inc. (DNLI) stock is 1.43M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Denali Therapeutics Inc. (DNLI) stock price going up or down today?

The stock price of Denali Therapeutics Inc. (DNLI) can change with earnings, company news, and overall market sentiment. Denali Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Denali Therapeutics Inc. stock expensive at its current price?

Whether Denali Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for DNLI on this page is -8.08. EPS on this page is -2.88. Compare those figures with peers and growth expectations before deciding if the current Denali Therapeutics Inc. price is justified.

How has the stock price of Denali Therapeutics Inc. (DNLI) performed historically?

Historical performance for Denali Therapeutics Inc. (DNLI) is shown on the price chart on this page. Review multi-period moves alongside volume to see how DNLI reacted to past earnings and market events.

Should I buy Denali Therapeutics Inc. (DNLI) stock, at this price?

Buying Denali Therapeutics Inc. (DNLI) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.